Drug Interaction:
Calcium Channel Blockers include -
Bepridil, Diltiazem, Felodipine, Isradipine, Nicardipine, Nifedipine,
Nimodipine, Verapramil, Amlodipine, Nisodipine, Clevidipine, Lercandipine
Refer verapramil-
Interacting drugs -summary-
+ Felodipine -
Barbiturates
Felodipine bioavailabilty decreased
Erythromycin
pharmacological & toxic eff of Felodipine increased
Cimetidine
bioavailabilty of Cimetidine increased
Ranitidine
bioavailablity of Ranitidine increased
Hydantoin
serum Felodipine levels decreased
Carbamazepine
increased carbamazepine serum levels with possible toxicity may occur. Plasma levels of felodipine may be decreased
Betablockers
coadministration may result in increased adverse effects due to depressant effects on myocardial contractility or AV conduction
Barbiturate
Felodipine plasma leveld and bioavailabilty may be reduced
Increases plasma digoxin concentration by approx 40%.
Concomittant admin of substances interfering with cytochrome P450 enzymes may affect plasma concentration of felodipine.
Plasma levels enhanced by enzyme inhibitors(eg Cimetidine).
Plasma levels reduced by enzyme inducers(eg Phenytoin, carbamazepine, barbiturates).
Concomittant admin of beta-blkrs reduces side effects.
Indication:
Hypertension
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Felodipine Anti-hypertensive May 1991
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Felodipine Cardiovascular AstraZeneca 19-06-2001
Felodipine Cardiovascular Merck 19-06-2001
Calcium Channel Blockers include - Bepridil, Diltiazem, Felodipine, Isradipine,
Nicardipine, Nifedipine, Nimodipine, Verapramil, Amlodipine, Nisodipine,
Clevidipine, Lercandipine
Refer verapramil-
Adverse Reaction:
FELODIPINE-
----------------
CNS - Headache 18% Dizziness/lightheadedness 6 %, Asthenia 5%,
Parathesia 3%,
Nervousness,Psychiatric disturbances,Depression, Amnesia,Paranoia, Psychosis,
Hallucinations , Somnolence, Insomina , Anxiety < 2%
GASTROINTESTINAL- Abdominal discomfort/cramps/dyspepsia 2 % Nausea 2%, Diarrhea
Constipation 2%, Vomting,dry mouth/thirst, Flatulence <2 %
CARDIOVASCULAR- Periph.edema 22%, Palpitation 2%,Hypotension, Syncope,
AV block 1,2,3 degree ,Myocardial infarction,Arrhythmias
unspecified, Angina, Tachycardia < 2 %
DERMATOLOGICAL- Dermatitis/rash 2 %, Pruritis/urticaria < 2 %
HAEMATOLOGICAL- Anemia < 2%
OTHER- Flushing 6% , Cough 3% Muscle cramps/ pain/inflammation,
joint stiffness, arthiritis < 2%,
Nasal or chest cong/sinusitis/ rhinitis , Mituration disorder,
polyuria/nocturia/dysuria/frequency, Sexual difficulties,
Shortness of breath/dyspepsis, wheezing , epistatixis, < 2%
Contra-Indications:
Hypersensitivity.Pregnancy including early stages.
Special precautions:
May cause rare hypotension with tachycardia resulting in myocardail ischemia in susceptible patients,severe liver disease.
Dosages/ Overdosage Etc:
Approved by FDA in May 1991
Indications:
Hypertension
Dosage:
Individualise dose. Initial dose - 5mg once daily. Usual dose varies between 5 to 10mg. Maximum dose is 20mg once daily.
Other Information:
For Availability/supplies
Contact -
1.Indian Drug Manufacturers Association (IDMA)
Phone- 022- 24944624/ 24974308
Fax- 022- 24950723
Email- idma@vsnl.com
Website: www.idma-assn.org
2.Bulk Drug Manufacturers Association (India)(BDMA)
Phone - 040-23703910/ 23706718
Fax- 040-23704804
Email- info@bdmai.org
Website: www.info@bdmai.org
Patient Information:
Refer verapramil-
Pharmacology/ Pharmacokinetics:
Refer - Verapramil- Calcium channel blockers
Interaction with Food:
Refer- Verapramil- Calcium channel blockers
Pregnancy and lactation:
Refer - Verapramil- Calcium channel blockers
Manufacturer Details